Molecular Profiles, a UK-based pharmaceutical development and manufacturing services provider, has invested in GMP hot melt extrusion (HME) technology along with other milling equipment. The expansion is part of a wider project focusing on enabling technologies to accelerate formulation development, particularly for complex molecules that are difficult to progress.
Rob Harris, chief technical officer at Molecular Profiles, said in a press statement that expanding the company’s in-house equipment would complement its expertise by bringing on-stream a diverse range of enabling technologies to assist drug developers in developing challenging compounds. According to Harris, the new enabling technologies division forms the backbone of the company’s early formulation development services, which primarily specialize in screening formulation options for challenging compounds, developing effective formulations, and finding solutions to meet clients’ product development requirements.
This investment marked a significant venture for Molecular Profiles. The company opened its new clinical production site in July 2013 following a successful inspection from the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Molecular Profiles manufactures a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds.
Source: Molecular Profiles